

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)



(10) International Publication Number
WO 2022/109328 A1

(51) International Patent Classification:

A61K 38/00 (2006.01) *A61P 37/02* (2006.01)
A61K 9/20 (2006.01) *A61P 1/00* (2006.01)
C07K 7/02 (2006.01) *A61P 7/00* (2006.01)
A61P 17/06 (2006.01)

(21) International Application Number:

PCT/US2021/060183

(22) International Filing Date:

19 November 2021 (19.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/116,568 20 November 2020 (20.11.2020) US
63/275,222 03 November 2021 (03.11.2021) US

(71) Applicants: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE). **PROTAGONIST THERAPEUTICS, INC.** [US/US]; 7707 Gateway Boulevard, Suite 140, Newark, California 94560 (US).

(72) Inventors: **DI PRETORO, Giustino**; Turnhoutseweg 30, 2340 Beerse (BE). **SUN, Dajun**; Turnhoutseweg 30, 2340 Beerse (BE). **RAJAN, Gopal**; Turnhoutseweg 30, 2340 Beerse (BE). **BROECKX, Geraldine**; Turnhoutseweg 30, 2340 Beerse (BE). **MERTENS, Nathalie**; Turnhoutseweg 30, 2340 Beerse (BE). **LI, Shu**; 7707 Gateway Boulevard, Suite 140, Newark, California 94560 (US). **LAI, Felix**; 7707 Gateway Boulevard, Suite 140, Newark, California

94560 (US). **MASJEDIZADEH, Mohammad**; 7707 Gateway Boulevard, Suite 140, Newark, California 94560 (US).


(74) Agent: **HOM, Roy K.**; Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR

FIG. 1



(57) Abstract: The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.

[Continued on next page]

WO 2022/109328 A1

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*